CGTX Soars 34.55% on FDA Phase 3 Trial Endorsement

On August 13, 2025, Cognition Therapeutics Inc. (CGTX) surged 34.55% in pre-market trading, marking a significant rise in its stock price.

Cognition Therapeutics has received the end-of-Phase 2 meeting minutes from the U.S. Food and Drug Administration (FDA), confirming alignment on the registrational path for Zervimesine (CT1812). This development is crucial as it indicates that the FDA supports the proposed design of the Phase 3 clinical trial for Zervimesine, a potential treatment for Alzheimer's disease.

The company's stock price has been volatile in recent months, but this latest news has provided a much-needed boost. The FDA's endorsement of the Phase 3 trial design is a positive sign for investors, as it suggests that the regulatory pathway for Zervimesine is clear and achievable.

Cognition Therapeutics has been working diligently to advance Zervimesine through the clinical trial process, and this latest development is a testament to their efforts. The company's management team has expressed optimism about the future of Zervimesine, and investors seem to share their enthusiasm.